The dataset shows filing activity concentrated among a mix of corporate, academic and government-linked assignees, several of which have filed steadily since the mid-2010s. A number of these historically active holders report zero filings in the most recent year, with year-on-year declines of 100%, which suggests either a strategic pivot or a slowdown in newly claimable architectures. Because publication lags filing by roughly 18 months, the most recent year understates true activity for every assignee, so a single quiet year should not be read as an exit without checking the trend over two or three prior years.

Filings rose from 334 in 2017 to a peak of 475 in 2019, held near that level through 2022 at 422, and have since trended down toward 85 in the partial 2026 year. That pattern is typical of a claim space where the foundational architectures, electrochemical transduction, immobilization chemistry, signal amplification, were staked out mid-decade, leaving later filers to work around dense prior art rather than open new ground. The apparent decline in the final one to two years should be discounted somewhat given publication lag.

G01N, material analysis and testing, appears in 7,741 of the 8,708 records in this dataset, making it the dominant classification by a wide margin. C12Q, covering enzyme and DNA measurement, is the clear second cluster at 3,443 records, followed by C12N (microorganisms and genetic engineering) and C12M (bioreactors and enzyme apparatus) in the low thousands and hundreds respectively. Smaller but active fronts include B01L lab apparatus, A61B diagnostic integration, C07K peptide chemistry, and B82Y nanotechnology, each in the low hundreds of records.

The most-cited records in this corpus are foundational electrochemical biosensor patents, several dating to the 1990s, including filings on electrochemical biosensor manufacture, interferant-eliminating biosensor designs, microfabricated biosensors, and biosensor membrane polymer chemistry. High citation counts here reflect decades of accumulated citation within a searched corpus rather than current commercial relevance, since older filings simply have had more time to be cited by everything that followed.

Filing density is thin, relative to the core G01N and C12Q clusters, in areas like aptamer-based signal amplification cascades, FET-gate biomolecular immobilization layers, nanomaterial-enhanced transduction linked to the B82Y classification, and multiplexed enzyme-electrode array selectivity. These are sub-areas that combine the core detection chemistry with a secondary technical element that has not attracted the same filing volume, which typically means claim space is still open rather than that the technology is unproven. A freedom-to-operate search focused specifically on those secondary IPC combinations, rather than the primary G01N code, is the more useful starting point for scouting.